Abstract
Coronaviruses (CoVs), a genus containing about 26 known species to date, cause highly prevalent diseases and are often severe or fatal in humans and animals. In 2003, a previously unknown coronavirus was identified to be the etiological agent of a global outbreak of a form of life-threatening pneumonia called severe acute respiratory syndrome (SARS). No efficacious therapy is currently available, and vaccines and drugs are under development to prevent SARSCoV infection in many countries. The CoV main protease (Mpro), which plays a pivotal role in viral gene expression and replication through a highly complex cascade involving the proteolytic processing of replicase polyproteins, is an attractive target for drug design. This review summarizes the recent advances in biological and structural studies, together with development of inhibitors targeting CoV Mpros. It is expected that inhibitors targeting CoV Mpros could be developed into wide-spectrum antiviral drugs against existing and possible future emerging CoV-associated diseases.
Keywords: Coronavirus, main protease, drug design
Current Pharmaceutical Design
Title: Drug Design Targeting the Main Protease, the Achilles Heel of Coronaviruses
Volume: 12 Issue: 35
Author(s): Haitao Yang, Mark Bartlam and Zihe Rao
Affiliation:
Keywords: Coronavirus, main protease, drug design
Abstract: Coronaviruses (CoVs), a genus containing about 26 known species to date, cause highly prevalent diseases and are often severe or fatal in humans and animals. In 2003, a previously unknown coronavirus was identified to be the etiological agent of a global outbreak of a form of life-threatening pneumonia called severe acute respiratory syndrome (SARS). No efficacious therapy is currently available, and vaccines and drugs are under development to prevent SARSCoV infection in many countries. The CoV main protease (Mpro), which plays a pivotal role in viral gene expression and replication through a highly complex cascade involving the proteolytic processing of replicase polyproteins, is an attractive target for drug design. This review summarizes the recent advances in biological and structural studies, together with development of inhibitors targeting CoV Mpros. It is expected that inhibitors targeting CoV Mpros could be developed into wide-spectrum antiviral drugs against existing and possible future emerging CoV-associated diseases.
Export Options
About this article
Cite this article as:
Yang Haitao, Bartlam Mark and Rao Zihe, Drug Design Targeting the Main Protease, the Achilles Heel of Coronaviruses, Current Pharmaceutical Design 2006; 12 (35) . https://dx.doi.org/10.2174/138161206779010369
DOI https://dx.doi.org/10.2174/138161206779010369 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Protein-protein Interactions: Network Analysis and Applications in Drug Discovery
Current Pharmaceutical Design New Viral Infection COVID-19: Current Status, Challenges and Possible Treatments
Letters in Drug Design & Discovery Coronavirus Disease -2019 (COVID-19) in 2020: A Perspective Study of a Global Pandemic
Current Pharmaceutical Design Are there any Therapeutic Options Currently Available for Wuhan Coronavirus?
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Current Trends and Future Strategies for the Global Impact of COVID-19 Pandemic
Coronaviruses New Coronavirus Outbreak
Current Pharmaceutical Analysis The Immunomodulatory Effects of Physical Activity
Current Pharmaceutical Design Expression of a Tagless Single-Chain Variable Fragment (scFv) of Anti-TNF-α by a Salt Inducible System and its Purification and Characterization
Protein & Peptide Letters Point of Care Ultrasound in Coronavirus 2019: Helpful or Not?
Current Respiratory Medicine Reviews Coronavirus in the Arena: One More Time
Current Respiratory Medicine Reviews An Urgent Industrial Scheme Both for Total Synthesis, and for Pharmaceutical Analytical Analysis of Umifenovir as an Anti-viral API for Treatment of COVID-19
Combinatorial Chemistry & High Throughput Screening The Bananins: New Anticorona-RNA-Viral Agents with Unique Structural Signature
Anti-Infective Agents in Medicinal Chemistry QT Interval Monitoring and Drugs Management During COVID-19 Pandemic
Current Reviews in Clinical and Experimental Pharmacology Do Genetic Factors Predispose People to COVID-19: A Review Article
Current Molecular Medicine Angiotensin-Converting Enzyme 2 Roles in the Pathogenesis of COVID-19
Current Hypertension Reviews Major Drugs Used in COVID-19 Treatment: Molecular Mechanisms, Validation and Current Progress in Trials
Coronaviruses Deep Sequencing Approaches to Antibody Discovery
Current Drug Discovery Technologies Transmissibility and Epidemicity of COVID-19 in India: A Case Study
Recent Advances in Anti-Infective Drug Discovery An Overview on COVID-19 and its Effect on Cardiovascular Diseases
Endocrine, Metabolic & Immune Disorders - Drug Targets The Interplay Among Epilepsy, Parkinson’s Disease and Inflammation: Revisiting the Link through Ca<sup>2+</sup>/cAMP Signalling
Current Neurovascular Research